Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy.

Cancer Cell Int · 2023 · PMC10657579 · PMID 37981695

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In our study, children with TP53 mutations showed a trend of adverse outcomes after CAR-T cell therapy, but without reaching a significant level; hence, further research is needed.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.